PA, NJ, DE-Israel Life Sciences Conference - Axendia

conversesoilBiotechnology

Dec 3, 2012 (4 years and 9 months ago)

221 views

PA, NJ, DE
-
Israel Life Sciences Conference

Israeli Company Survey

We look forward to your participation in the in the PA, NJ, DE
-
Israel Life Sciences Conference.

To help ensure that the program meets your needs and is attended by appropriate representati
ves from
the life sciences industry, funding organizations and other strategic partners from our region that are
well
-
matched to your business, AICC is seeking your input.

Please respond to this questionnaire and return it to the Israel Export Institute at

(add contact
information) no later
than
Aug

14
th
, 2008.

1.

Key Contact’s Information

a.

Company Name:

NexSig Neurologic

Examination Technologies, Ltd.

b.

Company Technology:


Device,


Biotechnology,


Pharmaceuticals,


Healthcare IT

c.

Company
Site
:

www.nexsig.com

d.

Delegate’s Name:

Dr. Allon Leibovitz

e.

Delegate’s Title:

CEO

f.

Delegate’s Phone:

+972 (54
)
44 44 923

2.

Company description and background and current financials
-

including investments. (50 word
limit)

NexSig was founded in 2004 by Prof. Amos Korczyn, a neurologist and a worldwide authority
on neurodegenerative diseases; and Dr. Ve
red Aharonson, an expert on biometric signal
processing and usability design and the recipient of a postdoctoral fellowship at Harvard
University.
NexSig has raised to date $1.5 million from Xenia VC (www.xenia.co.il),
KADIMA Life Sciences, and the Office
of Chief Scientist of the Israeli Ministry of Industry
and Trade.

3.

Product description including, target market, stage of development and major accomplishments
to date (50 word limit)

NexSig has develped a
technology
for c
ognitive
a
ssessment
.
Its flagship product, NexAde
™,
was validated in clinical studies which were published in peer reviewed articles, and is now
used in the field of Cognitive Assessment of
the Elderly
. NexSig is focused on the Wellness
Mar
ket, a very large and fast growing market, estimated at billions
of consumer dollars
annually. Our Go
-
To Market strategy is to gain recognition in the healthcare professional
community and leverage that to penetrate the wellness market. Implementation of this strategy
is successful:
NexSig has recently started to genera
te initial revenues from US and Israeli
customers
-

clinicians, researchers, food additives company, and wellness organizations.

4.

Are you seeking an investment?
Y/
N

a.

Amount



$
3 million


b.

Timeframe:



by
end of 2008

c.

Purpose:



Implement market penetration plan

to the US market

d.

Preferred Source:


Private investors; C
orporate VCs

5.

Listed below is a sampling of the key Life
-
Science constituents in our area. Based on

your
research, please identify all the organizations (whether or not listed) that you believe are
appropriate prospects for a strategic partnership with your company.

a.

For each company, please tell us what division or department within the company is best
suited to a collaboration with your company

b.

For each department, please identify the title of the most appropriate contact for your
meeting (examples
-
Director of R&D, Global Business Development, Medical Specialist,
Licensing Officer)


Ar
row International
:








AstraZeneca Pharmaceuticals LP
:







Baxter Healthcare Corp
:







Bristol
-
Myers Squibb Co.
:







Cephalon Inc.
:







Covatec
:







ENDO Pharmaceuticals
:








Genzyme Corp.
:







GlaxoSmith
-
Kline
:








Impax Laboratories I
nc
.
:







Johnson& Johnson



Centocor Biologics
:








Ethicon LLC
:







Janssen Pharmaceutical Inc
:








McNEIL
-
PPC Inc.
:








Ortho BioTech Inc.
:








Ortho Clinical Diagnostics
:







Lannett Co. Inc.
:







Laron Pharmaceuticals Inc.
:







Mennen Medical Corp.
:







Merck & Co Inc.
:







Kensey Nash Corp.
:







Novartis Pharmaceuticals Corp.
:







Pfizer Inc.
:







Quest Diagnostics
:






Roche



Pharmaceuticals
:








Diagnostics
:







Sanofi Aventis
:







Shire US Inc
.
:








Siemens Medical Solutions
:







ViroPharma Inc
.
:








West Pharmaceutical Services
:







Wyeth Pharmaceuticals
:







Zlb Behring LLC
:






6.

From the list below, please provide all additional areas for potential collaboration and resource
development for your company.

a.


Physicians/Health care practitioners

b.


Reimbursement

c.


Regulatory Issues

d.


Clinical Trials

e.


Healthcare Administrators

f.


Distribution

g.


Technology tra
nsfer

h.


Academia

i.


Incubators/Science Parks

j.


Licensing

k.


Medical Advisory

l.


Financial Advisory

m.


Clinical Development

n.


Intellectual Property

o.


Staffing

p.

Others (please list)